1
P.6.c. Addiction Drugs (basic) S567 P.6.c.004 Transdermal cannabidiol: long-lasting attenuation of relapse vulnerability in animal models of drug seeking, anxiety, and impulsivity F. Weiss , G. Gonzales-Cuevas 1 , A.L. Stinchcomb 2 1 The Scripps Research Institute, Cellular and Molecular Neuroscience Department (SP30–2120), La Jolla CA, USA; 2 AllTranz Inc., Lexington KY, USA Drug addiction is a chronically relapsing disorder. Susceptibility to relapse can be traced to multiple factors including craving elicited by drug-related cues, drug-induced neuroadaptation responsible for heightened anxiety and hypersensitivity to stress, as well as drug-induced impairments in impulse control as a risk factor for relapse. Given that addicted individuals enter vulnerability states for multiple reasons, treatment drugs that target more than a single factor or vulnerability state for relapse are likely to offer significant clinical advantages. An agent with an emerging profile of actions suggestive of potential to offer such a wide spectrum of actions is cannabidiol (CBD), the main non-psychoactive and non-addictive component of the Cannabis sativa plant. A factor limiting the therapeutic potential of CBD is the drug’s low oral bioavailability in man due to a major first-pass effect. Therefore, to provide for translational relevance in understand- ing CBD’s behavioral profile, the transdermal route of adminis- tration that eliminates the first pass effect and reduces bioavail- ability variability was employed. An initial experiment established that a transdermal CBD gel preparation (tCBD) produces dose- dependent significant and sustained plasma CBD levels with little variability. The effects of tCBD then were examined in animal models of relapse, anxiety, and impulsivity. Male Wistar rats with a history of ethanol or cocaine self-administration were treated with tCBD (gel volume: 640ml/kg = 15 mg/kg) at 24h intervals for 7 days. In repeated reinstatement tests conducted during this time, tCBD significantly reduced ethanol and cocaine seeking induced by drug-related cues, the pharmacological stressor yohimbine, or footshock stress, without producing tolerance. Remarkably, both stress- and cue-induced reinstatement remained fully attenuated in tests conducted as late as 138 days after termination of tCBD treatment. In tests of anxiety conducted 2 days post-tCBD, all rats showed significantly reduced anxiety-like behavior on the elevated plus maze. To study tCBD’s effects on impulse control, rats were subjected to a 7d ethanol intragastric intoxication pro- cedure during which they were treated at 24h intervals with tCBD (15 mg/kg). In subsequent delay discounting tests, rats with an intoxication history showed significantly reduced preference for large delayed reward. This profile of high impulsivity was fully reversed in tCBD-treated rats. In tests of nonspecific behavioral effects, tCBD neither interfered with reinstatement motivated by a palatable sweet solution, nor altered spontaneous locomotor activity. Although presently limited to a single dose, the results are consistent with the hypothesis that tCBD has therapeutic potential for multiple vulnerability states underlying relapse risk. Particularly significant was the observation that cue- and stress- induced ethanol seeking remained effectively reduced as late as 5 months (138 days) post-treatment. This observation, paired with the finding that tCBD attenuates impulsivity in rats with a severe ethanol intoxication history, is of substantial interest both from a medication development and neurobiological perspective in that it is suggestive of diverse neuroregulatory actions that restore normal function to brain circuitries regulating reward, incentive motivation, impulsivity, stress and anxiety. Support: NIH/ NIAAA AA018010 and NIH/NIDA DA07348 (FW); Fulbright MECD-2008 (GGC). P.6.c.005 Exposure to caffeine and sucrose changes locomotor behaviour, neurobiology and response to acute methamphetamine challenge J.L. Franklin , M. Mirzaei 2 , M.K. Sauer 1 , T.A. Wearne 1 , A.K. Goodchild 2 , P.A. Haynes 3 , J.L. Cornish 1 1 Macquarie University, Psychology, Sydney, Australia; 2 Macquarie University, Australian School of Advanced Medicine, Sydney, Australia; 3 Macquarie University, Chemistry and Biomolecular Sciences, Sydney, Australia Purpose: Caffeine is a psychostimulant that is commonly con- sumed by adults often in combination with high levels of sugar. There is evidence to suggest that caffeine treatment can change the psychostimulant response, in adult animals, to cocaine, nicotine or alcohol [1]. Sucrose exposure has also been shown to change reward pro- cessing [2]. Here we examined whether extended exposure to caffeine, sucrose or their combination altered the behavioral response to an acute methamphetamine (METH) challenge, as this drug is one of the highest abused substances in Australia and worldwide. In ad- dition to behavioural changes, the effect of chronic treatment with caffeine and or sucrose on protein expression in the orbitofrontal cortex (OFC) was examined. This brain region plays a critical role in decision making processes, with a number of neurodegenerative conditions linked to disruption of OFC function. Importantly, the OFC regulates impulse control and addictive disorders [3]. Method: Adult male Sprague Dawley (SD) rats, (n = 12 per group), were treated for 26 days with either water, caffeine (0.6g/L), 10% sucrose, caffeine (0.6g/L)+10% sucrose (C+S full) or caffeine (0.3g/L)+5% sucrose (C+S half) in their drinking water. Locomotor behaviour was measured on the first and last day of treatment, then again one week after treatment. Animals were then challenged with either saline (1 ml/kg, i.p.) or METH (1 mg/kg, i.p.) and their locomotor activity was measured for 2 hours prior to rapid removal of brain tissue; snap frozen in liquid nitrogen and then stored at −80 until label free quantitative shotgun proteomic analysis of the OFC was conducted. Results: When tested drug free and challenged with saline the caffeine pretreated animals were significantly more active than control and all other treatment groups (p < 0.05). Unex- pectedly caffeine pretreatment did not cross-sensitize the animals to METH, as the hyperactivity produced by METH was simi- lar in control rats compared to caffeine treated rats. However, hyperactivity produced by METH was significantly reduced in rats pretreated with combined caffeine and sucrose (full dose) when compared to those pretreated with caffeine alone (p = 0.035). Proteomic analyses of the OFC determined that 158 and 251 proteins were differentially expressed in caffeine and sucrose rats, respectively, when compared to control treated rats. The top functional networks associated with changed proteins in caffeine rats were nervous system function, cellular compromise and mi- tochondrial dysfunction, and in sucrose treated rats were nucleic acid metabolism, signaling, energy production and DNA repair.

P.6.c.004 Transdermal cannabidiol: long-lasting attenuation of relapse vulnerability in animal models of drug seeking, anxiety, and impulsivity

  • Upload
    al

  • View
    213

  • Download
    0

Embed Size (px)

Citation preview

Page 1: P.6.c.004 Transdermal cannabidiol: long-lasting attenuation of relapse vulnerability in animal models of drug seeking, anxiety, and impulsivity

P.6.c. Addiction − Drugs (basic) S567

P.6.c.004 Transdermal cannabidiol: long-lasting

attenuation of relapse vulnerability in

animal models of drug seeking, anxiety, and

impulsivity

F. Weiss1 °, G. Gonzales-Cuevas1, A.L. Stinchcomb2 1TheScripps Research Institute, Cellular and Molecular NeuroscienceDepartment (SP30–2120), La Jolla CA, USA; 2AllTranz Inc.,Lexington KY, USA

Drug addiction is a chronically relapsing disorder. Susceptibility torelapse can be traced to multiple factors including craving elicitedby drug-related cues, drug-induced neuroadaptation responsiblefor heightened anxiety and hypersensitivity to stress, as well asdrug-induced impairments in impulse control as a risk factor forrelapse. Given that addicted individuals enter vulnerability statesfor multiple reasons, treatment drugs that target more than asingle factor or vulnerability state for relapse are likely to offersignificant clinical advantages. An agent with an emerging profileof actions suggestive of potential to offer such a wide spectrumof actions is cannabidiol (CBD), the main non-psychoactive andnon-addictive component of the Cannabis sativa plant. A factorlimiting the therapeutic potential of CBD is the drug’s low oralbioavailability in man due to a major first-pass effect.Therefore, to provide for translational relevance in understand-

ing CBD’s behavioral profile, the transdermal route of adminis-tration that eliminates the first pass effect and reduces bioavail-ability variability was employed. An initial experiment establishedthat a transdermal CBD gel preparation (tCBD) produces dose-dependent significant and sustained plasma CBD levels with littlevariability. The effects of tCBD then were examined in animalmodels of relapse, anxiety, and impulsivity. Male Wistar rats witha history of ethanol or cocaine self-administration were treatedwith tCBD (gel volume: 640ml/kg = 15mg/kg) at 24h intervals for7 days. In repeated reinstatement tests conducted during this time,tCBD significantly reduced ethanol and cocaine seeking inducedby drug-related cues, the pharmacological stressor yohimbine, orfootshock stress, without producing tolerance. Remarkably, bothstress- and cue-induced reinstatement remained fully attenuatedin tests conducted as late as 138 days after termination of tCBDtreatment. In tests of anxiety conducted 2 days post-tCBD, allrats showed significantly reduced anxiety-like behavior on theelevated plus maze. To study tCBD’s effects on impulse control,rats were subjected to a 7d ethanol intragastric intoxication pro-cedure during which they were treated at 24h intervals with tCBD(15mg/kg). In subsequent delay discounting tests, rats with anintoxication history showed significantly reduced preference forlarge delayed reward. This profile of high impulsivity was fullyreversed in tCBD-treated rats. In tests of nonspecific behavioraleffects, tCBD neither interfered with reinstatement motivated bya palatable sweet solution, nor altered spontaneous locomotoractivity. Although presently limited to a single dose, the resultsare consistent with the hypothesis that tCBD has therapeuticpotential for multiple vulnerability states underlying relapse risk.Particularly significant was the observation that cue- and stress-induced ethanol seeking remained effectively reduced as late as≈5 months (138 days) post-treatment. This observation, pairedwith the finding that tCBD attenuates impulsivity in rats with asevere ethanol intoxication history, is of substantial interest bothfrom a medication development and neurobiological perspective inthat it is suggestive of diverse neuroregulatory actions that restore

normal function to brain circuitries regulating reward, incentivemotivation, impulsivity, stress and anxiety.Support: NIH/ NIAAA AA018010 and NIH/NIDA DA07348

(FW); Fulbright MECD-2008 (GGC).

P.6.c.005 Exposure to caffeine and sucrose changes

locomotor behaviour, neurobiology and

response to acute methamphetamine

challenge

J.L. Franklin1 °, M. Mirzaei2, M.K. Sauer1, T.A. Wearne1,A.K. Goodchild2, P.A. Haynes3, J.L. Cornish1 1MacquarieUniversity, Psychology, Sydney, Australia; 2Macquarie University,Australian School of Advanced Medicine, Sydney, Australia;3Macquarie University, Chemistry and Biomolecular Sciences,Sydney, Australia

Purpose: Caffeine is a psychostimulant that is commonly con-sumed by adults often in combination with high levels of sugar.There is evidence to suggest that caffeine treatment can change thepsychostimulant response, in adult animals, to cocaine, nicotineor alcohol [1].Sucrose exposure has also been shown to change reward pro-

cessing [2].Here we examined whether extended exposure to caffeine,

sucrose or their combination altered the behavioral response to anacute methamphetamine (METH) challenge, as this drug is one ofthe highest abused substances in Australia and worldwide. In ad-dition to behavioural changes, the effect of chronic treatment withcaffeine and or sucrose on protein expression in the orbitofrontalcortex (OFC) was examined. This brain region plays a critical rolein decision making processes, with a number of neurodegenerativeconditions linked to disruption of OFC function.Importantly, the OFC regulates impulse control and addictive

disorders [3].Method: Adult male Sprague Dawley (SD) rats, (n = 12 per

group), were treated for 26 days with either water, caffeine(0.6g/L), 10% sucrose, caffeine (0.6g/L)+10% sucrose (C+S full)or caffeine (0.3g/L)+5% sucrose (C+S half) in their drinkingwater. Locomotor behaviour was measured on the first and lastday of treatment, then again one week after treatment. Animalswere then challenged with either saline (1ml/kg, i.p.) or METH(1mg/kg, i.p.) and their locomotor activity was measured for2 hours prior to rapid removal of brain tissue; snap frozen inliquid nitrogen and then stored at −80 until label free quantitativeshotgun proteomic analysis of the OFC was conducted.

Results: When tested drug free and challenged with salinethe caffeine pretreated animals were significantly more activethan control and all other treatment groups (p< 0.05). Unex-pectedly caffeine pretreatment did not cross-sensitize the animalsto METH, as the hyperactivity produced by METH was simi-lar in control rats compared to caffeine treated rats. However,hyperactivity produced by METH was significantly reduced inrats pretreated with combined caffeine and sucrose (full dose)when compared to those pretreated with caffeine alone (p = 0.035).Proteomic analyses of the OFC determined that 158 and 251proteins were differentially expressed in caffeine and sucroserats, respectively, when compared to control treated rats. The topfunctional networks associated with changed proteins in caffeinerats were nervous system function, cellular compromise and mi-tochondrial dysfunction, and in sucrose treated rats were nucleicacid metabolism, signaling, energy production and DNA repair.